A New Dawn: Courage Against Cancer Funds Its First Preclinical Trial on the Path to FDA Approval

At Courage Against Cancer, we don’t just envision a future without chemotherapy and radiation as the only options—we are actively building it. Today, we are thrilled to announce a monumental leap forward in our mission: the funding of our first official preclinical research project.

This initiative represents the critical first step on a meticulously planned path to achieve a historic goal: securing FDA approval for ivermectin and mebendazole as safe and effective cancer therapies.

For decades, the cancer treatment landscape has been dominated by two powerful pillars: chemotherapy and radiation. While these tools have saved countless lives, they are often accompanied by significant side effects that diminish a patient’s quality of life. The financial toxicity can be equally devastating. We believe it’s time for a third pillar—a paradigm that is both effective and accessible.

This is where drug repurposing comes in. By investigating existing, widely available drugs with established safety profiles, we can bypass years of initial safety testing and exorbitant costs. This allows us to focus our resources on one question: Do these drugs work against cancer?

Our first targeted battlefield is ovarian cancer, a devastating disease where new hope is urgently needed. The research will be conducted at a world-renowned cancer center, a partnership that underscores the scientific credibility of our mission. While the details are confidential at this stage, the objective is clear and rigorous:

This preclinical trial is designed to systematically validate the anti-cancer effects of ivermectin and mebendazole in advanced laboratory models. The research will explore fundamental questions:

• Can these drugs effectively halt the growth of cancer cells?
• Do they show synergy with existing therapies, potentially making them more effective?
• What are the specific biological mechanisms that make them work?

The data generated from this study will be the foundation of our application to the U.S. Food and Drug Administration (FDA) to begin human clinical trials. This is the essential, non-negotiable first step in the marathon of drug development. There are no shortcuts, only the right steps.

It is too early to claim that these therapies will be the “first non-chemo, non-radiation” treatments approved. The path of science is one of discovery, and we must follow the data wherever it leads. The oncology field has seen the rise of other pillars, like immunotherapy and targeted therapy, which are powerful non-chemo options.

Our ultimate vision, however, is unique. We are not seeking to create a new, expensive, patented drug. We are fighting to validate widely available, affordable medicines. If successful, this could fundamentally shift the economics of cancer care, directly supporting our core pledge: to freely provide these treatments to children and indigent patients, alleviating both their disease and their financial burden.

This preclinical trial is more than just a study; it’s a signal flare. It signals to the world that a new, courageous approach to cancer research is underway. It is a testament to the power of your support, which is turning a bold idea into a tangible scientific reality.

The road ahead is long, but every journey begins with a single, decisive step. With this first preclinical trial, we have taken that step. We are moving from theory to action, from hope to data.

This is just the beginning. Stay with us. The courage to find a better way is now in the lab, and the results will shape the future.

---

This groundbreaking research represents the most promising path forward, but it cannot continue without your support. You have the power to directly accelerate this preclinical work and bring us closer to human trials. Your tax-deductible donation today isn’t just a contribution; it’s an investment in a future where a cancer diagnosis isn’t met with financial ruin. It funds the lab supplies, the data analysis, and the scientific rigor required to make our shared vision a reality for countless patients. Help us maintain this vital momentum.

---